These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 27911591

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Massive Ovarian Growth in a Woman With Severe Insulin-Resistant Polycystic Ovary Syndrome Receiving GnRH Analogue.
    Singh P, Agress A, Madrigal VK, Magyar C, Ostrzega N, Chazenbalk GD, Dumesic DA.
    J Clin Endocrinol Metab; 2019 Jul 01; 104(7):2796-2800. PubMed ID: 30759233
    [Abstract] [Full Text] [Related]

  • 3. Severe hyperandrogenism due to ovarian hyperthecosis in a young woman.
    Goyal A, Malhotra R, Kulshrestha V, Kachhawa G.
    BMJ Case Rep; 2019 Dec 17; 12(12):. PubMed ID: 31852694
    [Abstract] [Full Text] [Related]

  • 4. Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.
    Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE, Gorden P.
    J Clin Endocrinol Metab; 2010 Aug 17; 95(8):3641-7. PubMed ID: 20484479
    [Abstract] [Full Text] [Related]

  • 5. Hyperandrogenism in a postmenopausal woman: diagnostic and therapeutic challenges.
    Cheng V, Doshi KB, Falcone T, Faiman C.
    Endocr Pract; 2011 Aug 17; 17(2):e21-5. PubMed ID: 21247854
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism.
    Meczekalski B, Szeliga A, Maciejewska-Jeske M, Podfigurna A, Cornetti P, Bala G, Adashi EY.
    Gynecol Endocrinol; 2021 Aug 17; 37(8):677-682. PubMed ID: 33759685
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A.
    J Clin Endocrinol Metab; 2007 Nov 17; 92(11):4208-17. PubMed ID: 17785360
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antibody-Mediated Extreme Insulin Resistance: A Report of Three Cases.
    Kim HN, Fesseha B, Anzaldi L, Tsao A, Galiatsatos P, Sidhaye A.
    Am J Med; 2018 Jan 17; 131(1):102-106. PubMed ID: 28822702
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Source localization of androgen excess in adolescent girls.
    Ibáñez L, Potau N, Zampolli M, Prat N, Gussinyé M, Saenger P, Vicens-Calvet E, Carrascosa A.
    J Clin Endocrinol Metab; 1994 Dec 17; 79(6):1778-84. PubMed ID: 7989484
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of type B insulin resistance with rituximab.
    Manikas ED, Isaac I, Semple RK, Malek R, Führer D, Moeller LC.
    J Clin Endocrinol Metab; 2015 May 17; 100(5):1719-22. PubMed ID: 25675382
    [Abstract] [Full Text] [Related]

  • 19. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
    Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F.
    J Clin Endocrinol Metab; 2000 Oct 17; 85(10):3526-30. PubMed ID: 11061495
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.